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Goal:
This home-study CPE activity has been 
developed to educate pharmacists on 
updates in anti-platelet therapy after stent 
implantation.
Objectives:
At the conclusion of this lesson, successful 
participants should be able to:
1. Identify the mechanism of action and 
unique characteristics of the FDA-
approved P2Y
12
 receptor antagonists 
used in secondary prevention of 
cardiovascular disease.
2. Describe the recent recommendations 
regarding safety and efficacy for oral 
anti-platelet therapy post cardiac-stent 
placement. 
3. Compare the benefits and risks 
associated with each P2Y
12
 receptor 
antagonists based on presented 
clinical data. 
4. Select the appropriate anti-platelet 
therapy using patient-specific 
parameters for prevention of recurrent 
cardiac events.
Introduction
Despite advances in pharmacotherapy 
and technology, acute coronary syndromes 
(ACS) remains a significant healthcare 
issue with more than 1.2 million 
Americans suffering an ACS event 
annually.1  The usual culprit in ACS is an 
atheromatous plaque rupture which causes 
platelet activation and aggregation, leading 
to the propagation of the coagulation 
cascade. If untreated, the formation of a 
platelet-rich “white” clot will lead to an 
ACS event, which includes ST segment 
elevation myocardial infarction (STEMI), 
non-ST segment elevation myocardial 
infarction (NSTEMI) or unstable angina 
(UA).  Treatment options for ACS include 
percutaneous coronary interventions (PCI) 
with stent implantation, thrombolytic 
therapy, and/or medical management.
After the acute treatment of patients 
with ACS, the pharmacotherapy focus 
shifts to secondary prevention of 
cardiovascular events.  In patients who 
receive a stent implantation, one of the 
most important preventative measures 
is anti-platelet therapy to prevent both 
stent restenosis and in-stent thrombosis.  
Anti-platelet therapy for secondary 
prevention of cardiac events in the first 
year after ACS with PCI therapy and stent 
placement centers on several options:  
clopidogrel, prasugrel, ticagrelor, and 
aspirin.  The first 3 agents are P2Y
12
 
receptor antagonists while aspirin inhibits 
platelet cyclooxygenase-1.  Regardless of 
the mechanism, inhibition of these platelet 
pathways ultimately results in decreased 
platelet activation and aggregation.
For patients with implanted coronary 
stents, there are differing lengths of 
anti-platelet therapy based on the type 
of stent placed.2,3  The recommended 
therapy for bare metal stent placement 
include dual anti-platelet therapy with 
aspirin 75 - 325 mg daily and clopidogrel 
75 mg for 1 month, then low dose aspirin 
81 mg daily and clopidogrel 75 mg daily 
for the subsequent 11 months, and then 
single anti-platelet therapy with aspirin 
81 mg daily indefinitely thereafter.  The 
recommended therapy for drug-eluting 
stent placement include dual anti-platelet 
therapy with aspirin 75 - 325 mg with 
clopidogrel 75 mg daily for 3 - 6 months 
(minimum of 3 months for sirolimus-
eluting stent and 6 months for paclitaxel-
eluting stent), then low dose aspirin 
with clopidogrel 75 mg daily for 6 - 9 
months thereafter, and then single anti-
platelet therapy with aspirin 81 mg daily 
indefinitely (see Figure 1. for algorithm).4  
The 2011 American College of Cardiology 
Foundation/American Heart Association 
Task force on Practice Guidelines and the 
Society for Cardiovascular Angiography 
and Interventions (ACCF/AHA/SCAI) 
recommend indefinite aspirin 81 mg 
therapy in preference over higher doses 
in combination with P2Y
12
 receptor 
antagonists.  A minimum of 12 months of 
therapy with P2Y
12
 receptor antagonists 
is recommended with either a bare metal 
stent or drug-eluting stent if the patient is 
not at high risk of bleeding.  Continuation 
of therapy beyond 12 months may be 
considered for those with drug-eluting 
stent placement and low risk of bleeding 
(see Figure 2. for algorithm).2 
Both the CHEST and 2011 ACCF/AHA/
SCAI practice guidelines recommend 
the use of aspirin therapy with a P2Y
12
 
receptor antagonist post-cardiac stent 
implantation.  In contrast, the guidelines 
differ with regard to the preference 
given to the individual P2Y
12
 receptor 
antagonist.  The recent CHEST guidelines 
give preference to ticagrelor therapy over 
clopidogrel and prasugrel.2,4  Therefore, 
the focus of this review is to compare the 
similarities and differences in efficacy 
and safety between the 3 FDA-approved 
P2Y
12
 receptor antagonist:  clopidogrel, 
prasgurel, and ticagrelor.
Clopidogrel (Plavix®)
Clopidogrel is a second-generation 
thienopyridine which irreversibly 
inhibits the P2Y
12
 receptor on platelets.  
It is a pro-drug that requires hepatic 
biotransformation via CYP enzymes, 
particularly CYP2C19, to produce the 
active metabolite necessary to exert its 
pharmacological actions.5  The active 
metabolite formed in this process 
targets the P2Y
12
 receptor, one of the 
adenosine diphosphate (ADP) receptors 
on the platelet surface, to prevent platelet 
recruitment and activation of the GPIIb/
IIIa receptor complex; in so doing, platelet 
aggregation is reduced.6 Clopidogrel’s 
pharmacokinetic profile exhibits rapid 
dose absorption with or without food.7  
The conversion of the parent drug to 
active metabolite with maintenance 
dosing at 75 mg daily takes, on average, 
about two days to see inhibition of 
platelet aggregation (IPA) with peak 
effect occurring in 5 - 7 days.8  Due to 
the potential need for rapid inhibition of 
platelet aggregation, loading doses have 
been used to achieve faster therapeutic 
goals as studies have shown that peak IPA 
was able to be achieved within 6 hours 
with higher loading doses (300 mg, 600 
mg, 900 mg).9 
Although approximately half of the 
systemically circulating clopidogrel is 
cleared through the kidneys and the other 
half in the feces, there is limited data 
on the safety of this medication in renal 
impairment.  No adjustment is necessary 
for those with hepatic impairment. It 
is also important to consider that while 
the half-life of clopidogrel is relatively 
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short (~ 0.5 hour) compared to the 
parent compound (~ 6 hours), it binds 
irreversibly to the platelet receptors 
resulting in  normal platelet function of 
those blocked by clopidogrel to return 
with the development of new platelets.  
Platelet turnover takes approximately 7-10 
days which is how long it would take for 
normal platelet function to return after the 
last dose of clopidogrel is administered.4,7
Efficacy of clopidogrel in PCI
For patients with newly placed coronary 
stents, dual anti-platelet therapy with 
clopidogrel in addition to aspirin has 
shown to improve outcomes with long-
term therapy.  Data from studies such 
as the PCI-CURE trial which found 
significantly lower rates of cardiovascular 
(CV) death, myocardial infarction (MI), 
or any revascularization in patients 
undergone PCI with dual anti-platelet 
therapy beyond 4 weeks of treatment 
have helped to focus subsequent studies 
on the optimal length of therapy.10  The 
CREDO trial did just that and provided 
optimization for long-term anti-platelet 
therapy post-PCI when they found that 
there was relative reduction (26.9%) 
in combined CV events with at least 
a year of long-term dual therapy with 
clopidogrel and aspirin.11 These trials 
highlight the significant use of clopidogrel 
in this patient population; however, the 
following sections will address several 
considerations that should be made when 
choosing this agent.
Drug Interactions with Proton Pump 
Inhibitors
In an effort to maintain high therapeutic 
efficacy but minimize gastrointestinal (GI) 
toxicity from clopidogrel use, clinicians 
began adding on proton-pump inhibitor 
(PPI) treatment. While effective, in vitro 
data supported the notion that competitive 
inhibition by PPIs of CYP2C19 may 
alter the necessary metabolic step 
needed to produce the active metabolite 
of clopidogrel.12 The focus of current 
discussion is the therapeutic effect this 
interaction has on therapy outcomes. In 
the prospective randomized placebo-
controlled COGENT trial of 3,873 
patients, investigators assigned patients 
on dual anti-platelet therapy (clopidogrel 
75 mg and aspirin 75 mg - 325 mg daily) 
to either omeprazole 20 mg or placebo. 
The primary endpoint of composite 
gastrointestinal event as determined by 
bleeding ulcers, obstruction, or perforation 
addressed the potential benefits of 
gastrointestinal protection while on anti-
platelet therapy.  In addition, the primary 
safety endpoint composite of CV events 
as determined by death from CV causes, 
MI, revascularization, or stroke addressed 
the proposed interaction between 
clopidogrel and omeprazole on decreased 
anti-platelet activity.  The study found 
lower gastrointestinal events rates with 
omeprazole when compared to placebo; 
supportively, in the safety endpoint 
comparison, there was no difference in the 
risk of CV events or MI in the treatment 
groups.13 
In order to evaluate the effects of this 
interaction even further, a meta-analysis 
of twenty five studies (159,138 patients) 
was performed to assess the association 
of adverse events with combination 
therapy.  They found that combination 
therapy with PPIs (searched keywords 
of ‘pantoprazole,’ or ‘omeprazole’ or 
‘esomeprazole’ or ‘lansoprazole’ or 
‘rabeprazole’) with clopidogrel was 
associated with increased risks of major 
adverse CV events and MI at 29% 
and 31%, respectively.  However, PPI 
use was not associated with an overall 
increase in mortality.  Subgroup analyses 
of concomitant use of clopidogrel with 
either pantoprazole or omeprazole were 
not associated with an increased risk of 
major CV events.  While the analysis 
showed no influence on mortality, the 
investigators did find a decrease in the 
risk of developing GI bleed under PPI 
treatment by 50%.12
In lieu of the results presented in these 
trials, the Food and Drug Administration 
continues to warn against concomitant use 
of clopidogrel and PPIs, and recommends 
that combination treatment be used 
with caution.  It should be noted that 
this warning advisory does not apply to 
all PPIs as not all PPIs affect the CYP 
enzymes similarly.14  The ACCF/ACG/
AHA released a 2010 update on the 2008 
Expert Consensus Document on Reducing 
the Gastrointestinal Risks of Antiplatelet 
Therapy and NSAID Use stating that a 
small to moderate association can be made 
based on available evidence; however, 
further randomized controlled trials 
are needed to validate the associations 
found in observational studies. While 
several trials showed no significant 
association of CV events, the potential 
relative risk of CV events may warrant 
caution in combination therapy. The lack 
of consensus among trials confounds 
a clear association of PPI use with 
clopidogrel as the data is weak to establish 
decreased anti-platelet activity with 
coadministration.  Ultimately, treatment 
decisions need to assess whether the 
potential benefits outweighs potential 
harm as patients with prior upper GI 
bleeding and risk factors may benefit from 
prophylaxis against GI bleeding.15 
Decreased platelet responsiveness
In regards to anti-platelet efficacy, 
clopidogrel has a black box warning 
notifying that patients with genetic 
variability in CYP2C19 function, 
such as those with two nonfunctional 
alleles termed “poor metabolizers” of 
clopidogrel, may have reduced anti-
platelet activity.  Studies have suggested 
that high on-treatment platelet reactivity, 
those that require higher doses to achieve 
therapeutic effect, occurs in one-
third of those prescribed clopidogrel.4 
As a result, there have been higher 
cardiovascular event rates when this 
patient population is exposed to normal 
recommended doses when compared 
to those that do not have the decreased 
CYP2C19 function.  A meta-analysis 
compared the risk of major adverse 
cardiovascular events of clopidogrel 
administration between noncarriers 
(71.5%), heterozygotes (26.3%), or 
homozygotes (2.2%) of reduced-function 
CYP2C19 alleles that underwent PCI 
that had an ACS.  This study found that 
there was a significantly increased risk 
in both the patient populations with 1 
reduced-function CYP2C19 allele and 2 
reduced-function CYP2C19 alleles when 
compared to noncarriers. The analysis 
also found a significantly increased risk 
of stent thrombosis in both carriers of the 
reduced-function allele suggesting those 
patient populations with even 1 reduced-
function CYP2C19 allele may not be 
fully protected from cardiovascular events 
despite standard doses of clopidogrel.16 
Considering this patient population, there 
currently lacks support for the use genetic 
testing or platelet function testing to 
individualize anti-platelet therapy.3
Dosing and monitoring of clopidogrel
Clopidogrel is recommended to be 
administered as a 600 mg loading dose 
during PCI, followed by 75 mg daily 
maintenance dose.2  In addition to the 
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aforementioned precautions regarding 
PPIs, healthcare providers should be aware 
of other medications that are CYP2C19 
inhibitors.  Examples include fluconazole, 
voriconazole, and fluoxetine.
As with other medications in the 
thienopyridine class, there are risks 
of bleeding present with clopidogrel. 
Careful consideration in certain 
patient populations should be made 
as clopidogrel is contraindicated in 
those with active bleeding such as 
peptic ulcer or intracranial hemorrhage.  
Bleeding concerns have also prompted 
the recommendation to discontinue 
clopidogrel 5 days prior to surgery. 
When clopidogrel was stopped beyond 
5 days before a coronary artery bypass 
graft (CABG), rates of major bleeding 
were similar to those taking placebo. In 
comparison, patients who remained on 
clopidogrel within 5 days of a CABG, 
rates of major bleeding were higher at 
9.3% compared to 6.3% in the placebo 
group (see Table 1 for comparison chart).17 
Newer anticoagulants options:  
prasugrel and ticagrelor
Clopidogrel has been clinically proven 
to reduce recurrent cardiovascular 
events but clopidogrel has several 
limitations:  it is a pro-drug that requires 
hepatic conversion, has a delayed onset, 
and demonstrates a wide inter-patient 
variability and delayed recovery due to 
irreversible receptor binding.  Prasugrel 
and ticagrelor, two relatively new P2Y
12
 
receptor antagonists have been approved 
as alternatives to clopidogrel for patients 
with ACS undergoing PCI with stent 
placement.2,4  Both seek to address some 
of the issues faced with clopidogrel.
Prasugrel (Effient®)
Prasugrel was approved in 2009 for 
the reduction of recurrent cardiovascular 
events in patients with ACS who are 
undergoing PCI.  Similar to clopidogrel, 
prasugrel is a thienopyridine which 
irreversibly inhibits the P2Y
12
 receptor on 
the platelet.18  Prasugrel seeks to improve 
upon the shortcomings of clopidogrel 
with some key differences. While it is 
also a pro-drug, prasugrel is metabolized 
in the gastrointestinal tract and liver 
more rapidly than clopidogrel and the 
resulting metabolite binds irreversibly to 
the P2Y
12
 receptors on platelets inhibiting 
their aggregation without the need for a 
second activation step compared to two 
for clopidogrel. Also, prasugrel is not as 
adversely affected by individual genetic 
variations, which results in faster and 
more predictable platelet inhibition.5  It 
can reach peak concentration in as quickly 
as 30 minutes and last up to 7 hours.19 
Efficacy and safety of prasugrel
The TRITON-TIMI 38 phase 3 study 
sought to determine the safety and efficacy 
of prasugrel compared to clopidogrel 
in 13, 608 patients with ACS who were 
undergoing PCI.  Clopidogrel was 
administered as a 300 mg loading dose 
then 75 mg daily while the comparator 
group was administered prasugrel 60 mg 
loading dose then 10 mg daily for 6 to 15 
months.  The study measured the primary 
efficacy endpoints of death from CV 
causes, nonfatal MI, and nonfatal stroke, 
while the incidence of major bleeding 
was the major safety endpoint.  It was 
observed that in addition to a significantly 
lower number of primary efficacy 
endpoint events with prasugrel (9.9%) as 
compared with clopidogrel (12.1%), the 
prasugrel group also had fewer rates of 
MI, target-vessel revascularization, and 
stent thrombosis.  However, the added 
benefit of increased efficacy came with the 
drawback of a higher incidence of major 
and life-threatening bleeding events in the 
prasugrel group.20
Due to this increased risk of bleeding 
in the total study population, further 
subgroup analyses were performed to 
determine whether or not certain patient 
populations would experience a greater 
net clinical benefit from prasugrel, with 
the reduction in cardiovascular events 
outweighing the bleeding risk.  To answer 
these questions, 2 separate subgroup 
analyses were performed on patients 
with diabetes and with a STEMI.  Of the 
total 13,608 patients in the TRITON-
TIMI 38 trial, the first subgroup analysis 
trial explored the safety and efficacy of 
prasugrel versus clopidogrel in the 3,146 
patients with diabetes mellitus (DM).  
From a primary efficacy standpoint, there 
were significantly fewer incidents of (CV 
death, non-fatal MI, or non-fatal stroke) 
with prasugrel compared to clopidogrel in 
both the diabetic (9.2% versus 10.6%) and 
non-diabetic (12.2% versus 17%) groups.  
In contrast to the findings in the original 
TRITON-TIMI 38 trial, the diabetic 
subgroup in this study did not have an 
increased risk of major bleeding compared 
to clopidogrel (2.6% versus 2.5%).  For 
patients on prasugrel, the greater relative 
reduction in incidents of the primary end 
point and MI events without an observed 
increase in major bleeding provided a 
greater net clinical benefit when compared 
to clopidogrel.21 
The other subgroup analysis included 
3,534 participants with STEMI treated 
with either prasugrel or clopidogrel.  The 
primary endpoint was a composite of CV 
death, non-fatal MI, or non-fatal stroke 
at 30 days and at 15 months.  Compared 
to clopidogrel, the prasugrel group had 
a significantly lower incidence of the 
primary efficacy endpoint at both 30 days 
(9.5% vs. 6.5%) and at 15 months (12.4% 
vs. 10%).  There was no significant 
difference in major bleeding unrelated 
to CABG surgery between both groups; 
similarly, no difference was reported in 
life-threatening bleeding, intracranial 
hemorrhage, or minor bleeding at 15 
months.  However, it was observed that 
patients on prasugrel who underwent 
CABG surgery experienced an increased 
risk for major bleeding compared to those 
on clopidogrel.22  Therefore, STEMI 
patients may also be a population in 
which prasugrel demonstrates a greater 
net clinical benefit when compared to 
clopidogrel.
Although prasugrel showed additional 
benefits for diabetics and those who 
have STEMIs, it is important to note 
that neither of these subgroup analyses 
were designed or powered for all clinical 
endpoints in the population, and the 
small sample size may have skewed the 
results.21, 22
Dosing and monitoring of prasugrel
In patients undergoing PCI with 
stent placement, prasugrel is typically 
administered as a single 60 mg loading 
dose followed by a maintenance dose of 
10 mg once daily if the patient weighs 
more than 60 kg.  Patients with lower 
body weights may have an increased risk 
of bleeding and it is recommended that a 
lower 5 mg maintenance dose be used for 
those weighing less than 60 kg.2, 23  It must 
be noted, however, that although a lower 
maintenance dose is recommended for 
lower weight patients, safety and efficacy 
at this dose has not yet been studied.    
Most of the contraindications and 
warnings center on patients with these 
risks due to the increased incidence of 
major and potentially fatal bleeding seen 
in the prasugrel trials when compared 
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to clopidogrel.  It is contraindicated in 
patients with active pathological bleeding, 
history of transient ischemic attack (TIA) 
or stroke.  Other high risk populations 
with an increased risk of bleeding include 
patients older than 75 years, weigh less 
than 60 kg, have a propensity to bleed, and 
are using concomitant medications that 
increase bleeding risk.  Examples of these 
medications include warfarin, NSAIDS or 
fibrinolytic therapy.  While it is generally 
not recommended to use prasugrel in 
patients older than 75 years, it may be 
considered in patients with diabetes or 
STEMI, as those groups demonstrated a 
greater net clinical benefit compared to the 
total study population.21 
Prasugrel should be stopped at least 
7 days before CABG with the extra 
time required due to the longer half-
life.21 If possible, it is recommended 
that any bleeding be managed without 
discontinuing the medication due to 
increased risk of cardiovascular events 
if stopped prematurely.  Practitioners 
managing these patients should also 
consider other common adverse 
drug events, including hypertension, 
hyperlipidemia, head and backaches, 
dyspnea, nausea and vomiting.  
Concomitant use of medications that 
increase bleeding risk should  be avoided 
if possible, but interactions with CYP 
inducers or inhibiters were not significant.  
Fortunately, there is no renal dosing and 
the lower CYP activation means that no 
dose adjustment is needed in patients with 
mild to moderate hepatic impairment (see 
Table 1 for comparison chart).23
Ticagrelor (Brilinta®)
Ticagrelor is classified as a cyclopentyl-
triazolpyrimidine.  It binds reversibly to 
the P2Y
12
 receptor at an allosteric site, 
changes the receptor conformation, and 
prevents ADP-stimulated activation of 
the glycoprotein IIb/IIIa receptor and 
attenuating platelet aggregation.5  Unlike 
clopidogrel and prasugrel, ticagrelor 
is not a pro-drug and does not require 
metabolism to an active form.  It is also 
broken down into at least one active 
metabolite with a similar potency to 
the parent drug.  This combination of 
properties produces a rapid onset of action 
within 30 minutes, and a peak inhibitory 
effect in 2 hours.5 
Efficacy and safety of ticagrelor
The landmark phase 3 PLATO trial 
compared the safety and efficacy of 
ticagrelor with clopidogrel for prevention 
of cardiovascular events in patients with 
ACS.26  Ticagrelor was given as a 180 mg 
loading dose then 90 mg twice daily and 
clopidogrel was given as a 300 – 600 mg 
loading dose then 75 mg daily.  This study 
followed 18,624 patients over 12 months 
to determine the outcomes for a primary 
efficacy end point designated as time to 
the first occurrence of a composite of 
death from vascular causes, MI or stroke 
and primary safety endpoints of first 
occurrence of major bleeding.26  It was 
observed that ticagrelor (9.8%) showed 
greater efficacy in preventing the primary 
efficacy end points than clopidogrel 
(11.7%) and the incidents of major 
bleeding were similar between the two 
groups (ticagrelor 11.6% vs. clopidogrel 
11.2%).  Unfortunately, patients on 
ticagrelor did experience a higher rate 
of non–CABG-related major bleeding, 
intracranial bleeding and dyspnea.26 
 The PLATO trial discovered an 
anomaly in which ticagrelor was 
significantly less effective in North 
American patients compared to the rest 
of the world. The North American sub-
study sought to determine the possible 
causes of this difference, and identified 
an underlying statistical interaction with 
aspirin maintenance dose.  Of the 37 
factors explored, only the maintenance 
aspirin dose emerged as a possible 
explanation for the regional differences.23  
Analysis revealed that more patients 
in the United States (53.6%) took a 
higher maintenance dose of aspirin > 
300 mg than the rest of world (1.7%) 
and that low-dose maintenance aspirin 
concomitantly with ticagrelor had better 
outcomes compared to clopidogrel.  
The authors of the study theorized that 
aspirin’s dose dependent inhibition of 
endothelial prostacyclin may reduce the 
anti-platelet effect of ticagrelor at higher 
doses.  However, they do acknowledge 
that further research is needed to elucidate 
the possible mechanism of this interaction 
and that chance cannot be ruled out given 
the current data.23  Based on the current 
available data, it is recommended that 
ticagrelor should only be administered 
with low-dose maintenance aspirin.23
Dosing and monitoring of ticagrelor
Patients being started on ticagrelor 
should be given an initial loading dose 
of 180 mg at the time of PCI, and then 
continued on a maintenance dose of 90 
mg twice daily.24  Ticagrelor is primarily 
metabolized by hepatic CYP3A4 
enzymes so it is susceptible to drug 
interactions with medications that inhibit 
or induce these enzymes.  Concomitant 
use of inducers such as rifampin or 
phenytoin and inhibitors such as azoles, 
clarithromycin or protease inhibitors 
should be avoided.  Ticagrelor can reduce 
the metabolism of other drugs which are 
CYP3A4 substrates such as simvastatin, 
resulting in a higher serum simvastatin 
concentration and an increased risk of 
rhabdomyolysis.  Serum levels of digoxin, 
a medication with a narrow therapeutic 
window, must also be monitored closely if 
used concomitantly with ticagrelor.24
Due to an increased risk of bleeding, 
ticagrelor has a black box warning 
cautioning against use in patients with a 
history of intracranial hemorrhage and 
active bleeding.24  It is also recommended 
to discontinue ticagrelor at least 5 days 
prior to CABG.  It is important to note that 
the warning label advises to try managing 
bleeding episodes while remaining on 
ticagrelor as premature discontinuation 
increases the risk of cardiovascular 
events.  Also included in the black box 
warning is the recommendation for use 
with aspirin 81 mg for efficacy.  It is also 
advised against the use in patients with 
severe hepatic impairment.24  Dyspnea was 
a common adverse effected noted with 
ticagrelor, occurring in approximately 
14% of patients studied within the first 
few weeks after medication initiation.  
Other noted adverse events include, 
asymptomatic bradycardia, and ventricular 
pauses.24  There have been reported cases 
of increase in uric acid levels as well, 
so caution should be taken in patients 
with a history of gout (see Table 1 for 
comparison chart).
The safety and efficacy of ticagrelor in 
elderly patients is of particular concern 
because while this population is at 
increased risk of cardiac complications, 
they are also at higher risks of bleeding.  
Fortunately, the PLATO trial did not 
identify any difference in safety or 
efficacy between younger and older 
patients, although it is recommended that 
older patients be monitored more carefully 
for bleeding complications. 
General Considerations: P2Y
12
 receptor 
antagonists
Patients should be counseled on the 
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importance of continuing dual anti-platelet 
therapy for the full recommended duration 
because early discontinuation can result in 
recurrent cardiovascular events.  Another 
important counseling area includes the 
increased risk for bleeding and patients 
should be taught to be aware of certain 
things, such as signs and symptoms 
of bleeding (dark colored urine and 
stool).   These patients will bruise more 
easily, and take longer than usual to stop 
bleeding. They should promptly report 
any unanticipated, prolonged, or excessive 
bleeding immediately to their health care 
provider.
Pharmacist’s Role
With these newer anti-platelet agents, 
pharmacists can play a pivotal role in 
both monitoring and educating patients, 
whether in hospital, clinic, or community 
settings.  Each of the agents discussed 
may provide enhanced benefit to specific 
patient populations. However, they also 
come with additional precautions, possible 
adverse events and interactions that 
must be carefully evaluated along with 
patient specific information, evidenced 
based research and clinical judgment to 
determine the best course of treatment.  
These new drugs provide extra tools 
in the healthcare provider arsenal for 
treating patients undergoing PCI with stent 
placement.  As the medication experts, 
pharmacists are uniquely qualified to help 
match up the right drug to the right patient 
and ensure optimal treatment outcomes. 
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Figure 2.  Anti-platelet therapy recommendations from 2011 ACCF/AHA/SCAI practice guidelines2  
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Inhibition of platelet 
aggregation 
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Dose-dependent: 
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Dose-dependent: 
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Renal adjustment No No No 
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hepatic impairment 
Table 1. Comparison of P2Y12 receptor antagonists
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1.  Clopidogrel acts primarily by :
a.  Stimulating the ADP receptors on the platelet 
surface
b.  Increasing platelet aggregation via P2Y
12 
receptors  
c.  Inhibiting the P2Y
12
 receptor on platelets 
d.  None of the above
2.  Which of the following statements is correct and 
may explain the differences in onset of action of the 
3 drugs?
a.  Clopidogrel , prasugrel and ticagrelor are all pro 
drugs
b.  Only clopidogrel is a pro drug.  Prasugrel and 
ticagrelor are active medications
c.  Only ticagrelor is a pro drug.  Clopidogrel and 
prasugrel are active medications
d.  Both clopidogrel and prasugrel are pro drugs.  
Ticagrelor is an active medication
3.  The black box warning for ticagrelor: 
a.  Cautions against use in patients with a history of 
intracranial hemorrhage and active bleeding
b.  Warns that patients with genetic variability in 
their CYP2C19 allele may have reduced anti-
platelet activity
c.  Advises against use in patients ≥ 75 years  with 
the exception of high risk situations
d.  Advises to avoid use in patients with unstable 
angina due to increased bleeding risk
4.  Which potential drug-drug interaction has 
continued warnings because of the potential 
increase in cardiovascular events with concomitant 
use?
a.  Clopidogrel and aspirin 
b.  Ticagrelor and proton pump inhibitors
c.  Prasugrel and aspirin 
d.  Clopidogrel and proton pump inhibitors
5.  What is the minimum length of time for 
thromboembolic prophylaxis for PCI patients with 
a sirolimus-eluting stent on clopidogrel, ticagrelor 
or prasugrel?
a.  Patients may be transitioned off prophylaxis after 
1 month if they are at low risk for a thromboembolic 
event. 
b.  Treatment should be discontinued immediately 
after PCI if the patient is not in a high risk group
c.  Treatment should be continued indefinitely 
due to the high risk for thromboembolic events 
following PCI
d. ost patients should be treated for a minimum of 
12 months
6.  The North American sub study of ticagrelor 
found that:
a.  Patients on lower maintenance doses of aspirin 
(< 300 mg) concomitantly with ticagrelor had better 
outcomes
b.  Ticagrelor is best taken on an empty stomach as 
higher gastrointestinal pH increases bioavailability
c.  Ticagrelor is teratogenic and should be avoided 
in patients who are pregnant or planning to become 
pregnant within 6 months 
d.  Ticagrelor patients on aspirin therapy 
experienced significantly lower gastrointestinal 
complications when using a PPI for prophylaxis
7.  Which of the following statements is incorrect?
a.  The active metabolite for ticagrelor binds 
reversibly to the P2Y
12
 receptor
b.  Clopidogrel requires dose adjustment for hepatic 
impairment 
c.  Inter-patient genetic variability has less effect on 
prasugrel than clopidogrel.
d.  All of the above statements are correct
8.  Which of the following statements is correct 
regarding platelet inhibition?
a.  Clopidogrel has a faster platelet inhibition time 
than prasugrel  but slower than ticagrelor
b.  All three drugs have similar platelet inhibition 
times
c.  Ticagrelor and prasugrel have faster platelet 
inhibition times than clopidogrel
d.  None of the above statements are correct
9.  Which of the following is an appropriate 
protocol for dosing prior to a CABG procedure?
a.  Hold ticagrelor  for 1 day prior to CABG
b.  Hold prasugrel for 7 days prior to CABG
c.  Hold clopidogrel for 2-3 days prior to CABG
d.  All of the drugs should be held no longer than 
1-2 days prior to CABG
10.  55 year-old, 50 kg patient is admitted for 
STEMI, and is taken to the cardiac catherization 
lab for primary PCI.  The patient has a past medical 
history of hypertension and a transient ischemic 
attack in 2005.  Her renal and hepatic function are 
within normal limits.  Current medications include 
aspirin 325 mg daily, metoprolol 25 mg twice 
daily, and atorvastatin 20 mg daily.  Which of the 
following is the BEST recommendation for anti-
platelet therapy for this patient?
a.  Clopidogrel 600 mg loading dose, then 75 mg 
daily
b.  Prasugrel 20mg mg loading dose, then 10 mg 
daily
c.  Prasugrel 60 mg loading dose, then 10 mg daily
d.  Ticagrelor 180 mg loading dose, then 90 mg 
twice daily
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